Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy
Status: | Recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/9/2019 |
Start Date: | December 15, 2017 |
End Date: | March 2020 |
Contact: | TARIS Biomedical LLC |
Email: | clinops@tarisbio.com |
Phone: | +1-971-676-7750 |
A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
The purpose of this study is to determine if TAR-200, an investigational drug-delivery
system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are
unfit for radical cystectomy (RC) during an 84-day induction period comprised of four
consecutive 21-day dosing cycles.
system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are
unfit for radical cystectomy (RC) during an 84-day induction period comprised of four
consecutive 21-day dosing cycles.
Inclusion Criteria:
1. Histological proof of non-metastatic muscle-invasive urothelial cell carcinoma of the
bladder.
2. Subject must have been as fully resected as possible per the physician's judgment.
3. Subjects must be deemed unfit for RC due to comorbid conditions with a risk of
mortality.
4. Subjects must refuse or be deemed ineligible for cisplatin-based chemotherapy.
5. Subject must refuse or not be eligible for radiotherapy.
6. Life expectancy of at least 4 months.
7. Adequate bone marrow, liver, and renal function.
8. Subjects must be willing to undergo a cystoscopy.
9. Subjects must be willing to undergo a biopsy for assessment of clinical response.
10. Written informed consent and authorization for release of personal health information
obtained according to local laws.
11. Age ≥18 years at the time of informed consent.
12. Females of childbearing potential must be willing to use an effective method of
contraception (hormonal or barrier method of birth control; abstinence) from the time
consent is signed until 4 weeks after treatment discontinuation. Subject's partner
must also use barrier protection while subject is on study until 4 weeks after
treatment discontinuation.
13. Males must be willing to use an effective method of contraception/method to avoid
seminal transfer (barrier method or abstinence) from the time consent is signed until
4 weeks after treatment discontinuation. Subject's partner must also use barrier
protection while subject is on study until 4 weeks after treatment discontinuation.
14. Females of childbearing potential must have a negative pregnancy test within 21 days
prior to Study Day 0.
Exclusion Criteria:
1. Other active malignancies.
2. Presence of any bladder or urethral anatomic feature that in the opinion of the
Investigator may prevent the safe placement, indwelling use, or removal of TAR-200.
3. Pyeloureteral tube externalized to the skin (ureteral stent or unilateral nephrostomy
tube is allowed).
4. Evidence of bladder perforation during diagnostic cystoscopy.
5. Bladder post-void residual volume (PVR) of >750 mL.
6. Concurrent clinically significant infections as determined by the treating
Investigator.
7. Known hypersensitivity to gemcitabine (or other drug excipients) or chemically related
drugs.
8. Known hypersensitivity to the device constituent or TARIS Inserter materials.
9. Use of an investigational product within 30 days or 5 half-lives, whichever is longer,
preceding Study Day 0.
10. Female subject who is lactating/breastfeeding.
11. Difficulty providing blood samples.
12. Unwilling or unable to provide informed consent or comply with the requirements of
this protocol, including the presence of any condition (physical, mental or social)
that is likely to affect the subject's return for scheduled visits and follow-up.
13. Other unspecified reasons that, in the opinion of the Investigator, make the subject
unsuitable for enrollment.
We found this trial at
8
sites
601 Elmwood Avenue
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2100
Phone: 585-275-0126
Univ of Rochester Medical Center One of the nation's top academic medical centers, the University...
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Phone: 615-434-2120
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
2801 Charlotte Avenue
Nashville, Tennessee 37209
Nashville, Tennessee 37209
Phone: 615-250-9268
Click here to add this to my saved trials
Mayo Clinic Mayo Clinic's campus in Arizona provides medical care for thousands of people from...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials